Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas

Diabetes

Volumn 57, Issue 4, 2008, Pages 1026-1033

  Zhang, Xinyuan ^a,b,d   Bao, Shisan ^c   Lai, Donna ^c   Rapkins, Robert W ^a   Gillies, Mark C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c UNIVERSITY OF SYDNEY   (Australia)

^d SYDNEY EYE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA ACTIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; GLUCOCORTICOID; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DIABETIC MACULAR EDEMA; DRUG MECHANISM; EXTRAVASATION; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PERMEABILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RETINA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHAM PROCEDURE; SINGLE DRUG DOSE; STREPTOZOCIN DIABETES; THICKNESS; TRANSCRIPTION REGULATION; ANIMAL; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; GENETICS; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD-RETINAL BARRIER; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DISEASE PROGRESSION; GLUCOCORTICOIDS; MALE; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 42449092862     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db07-0982     Document Type: Article

References (45)

1. Kohner EM: Diabetic retinopathy and high blood pressure: defining the risk. Am J Hypertens 10:181S-183S, 1997
2. Group ETDRSR: Effects of asprin treatment on diabetic retinopathy ETDRS report number 8. Opthalmology 98 (Suppl.):757-765, 1991
3. Sander B, Larsen M, Moldow B, Lund-Andersen H: Diabetic macular edema: passive and active transport of fluorescein through the blood-retina barrier. Invest Ophthalmol Vis Sci 42:433-438, 2001
4. Engler CB, Sander B, Larsen M, Koefoed P, Parving HH, Lund-Andersen H: Probenecid inhibition of the outward transport of fluorescein across the human blood-retina barrier. Acta Ophthalmol (Copenh) 72:663-667, 1994
5. Vinores SA, McGehee R, Lee A, Gadegbeku C, Campochiaro PA: Ultra-structural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats. J Histochem Cytochem 38:1341-1352, 1990
6. Xu Q, Qaum T, Adamis AP: Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 42:789-794, 2001
7. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408-2413, 2001
8. Mathews MK, Merges C, McLeod DS, Lutty GA: Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy. Invest Ophthalmol Vis Sci 38:2729-2741, 1997
9. Schwesinger C, Yee C, Rohan RM, Joussen AM, Fernandez A, Meyer TN, Poulaki V, Ma JJ, Redmond TM, Liu S, Adamis AP, D'Amato RJ: Intracho-roidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol 158:1161-1172, 2001
10. Mukhopadhyay D, Nagy JA, Manseau EJ, Dvorak HF: Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res 58:1278-1284, 1998
11. Cebe-Suarez AZ-FaKB-H: The role of VEGF receptors in angiogenesis; complex partnerships. Cell Mol Life Sci 63:601-615, 2006
12. Cunningham ET, Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ, Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz SD: A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112:1747-1757, 2005
13. Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP: Pe-gaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 114:1702-1712, 2007
14. Jonas JB, Kreissig I, Sofker A, Degenring RF: Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121: 57-61, 2003
15. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C: Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920-927, 2002
16. Edelman JL, Lutz D, Castro MR: Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res 80:249-258, 2005
17. Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, Musashi K, Yoshimura N: Intravitreal injection of corticosteroid attenuates leuko-stasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 46:1440-1444, 2005
18. Gillies MC, Sutter FKP, Simpson JM, Larsson J, Ali H, Zhu M: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113:1533-1538, 2006
19. Murata TNK, Khalil A, Ishibashi T, Inomata H, Sueishi K: The relation between expression of vasucular endothelial growth factor and breakdown of blood-retinal barrier in diabetic rat retina. Lab Invest 74:819-825, 1996
20. Miyamoto K, Hiroshiba N, Tsujikawa A, Ogura Y: In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 39:2190-2194, 1998
21. Murata TIT, Inomata H: Immunohistochemical detection of blood-retinal barrier breakdown in steptozotocin-diabetic rats. Graefe's Archive for Clinical and Experimental Ophthalmology 231:175-177, 1993
22. Nicholls SJ, Cutri B, Worthley SG, Kee P, Rye KA, Bao S, Barter PJ: Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 25:2416-2421, 2005
23. Francisco JS, Moraes HP, Dias EP: Evaluation of the Image-Pro Plus 4.5 software for automatic counting of labeled nuclei by PCNA immunohisto-chemistry. Pesqui Odontol Bras 18:100-104, 2004
24. Ramsay AJ, Husband AJ, Ramshaw IA, Bao S, Matthaei KI, Koehler G, Kopf M: The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264:561-563, 1994
25. Ojima T, Takagi H, Suzuma K, Oh H, Suzuma I, Ohashi H, Watanabe D, Suganami E, Murakami T, Kurimoto M, Honda Y, Yoshimura N: EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. Am J Pathol 168:331-339, 2006
26. Lafuente JV, Argandona EG, Mitre B: VEGFR-2 expression in brain injury: its distribution related to brain-blood barrier markers. J Neural Transm 113:487-496, 2006
27. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO: Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22:1-29, 2003
28. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995, 1994
29. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N: Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): a reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276: 3222-3230, 2001
30. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT: Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 81:154-162, 1997
31. Hammes HP, Lin J, Bretzel RG, Brownlee M, Breier G: Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 47:401-406, 1998
32. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M: Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113:1533-1538, 2006
33. Barnes PJ: Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 94:557-572, 1998
34. Felinski EA, Antonetti DA: Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res 30:949-957, 2005
35. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW: Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1: a potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 274:23463-23467, 1999
36. Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC Jr.: Hydro-cortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 80:667-677, 2002
37. Heier JS, Antoszyk AN, Pavan PR, Leff SR, Rosenfeld PJ, Ciulla TA, Dreyer RF, Gentile RC, Sy JP, Hantsbarger G, Shams N: Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 113:642 e641-644, 2006
38. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Jr, Esquiabro M: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Oph-thalmol 143:566-583, 2007
39. Gillies MC, Tien YW.: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 356:747-750, 2007
40. van Wijngaarden P, Coster DJ, Williams KA: Inhibitors of ocular neovas-cularization: promises and potential problems. JAMA 293:1509-1513, 2005
41. Wenzel A, Grimm C, Seeliger MW, Jaissle G, Hafezi F, Kretschmer R, Zrenner E, Reme CE: Prevention of photoreceptor apoptosis by activation of the glucocorticoid receptor. Invest Ophthalmol Vis Sci 42:1653-1659, 2001
42. Vinores S: Assessment of blood-retinal barrier integrity. Histol Histopath 10:141-154, 1995
43. Bahcekapili N, Uzum G, Gokkusu C, Kuru A, Ziylan YZ: The relationship between erythropoietin pretreatment with blood-brain barrier and lipid peroxidation after ischemia/reperfusion in rats. Life Sci 80:1245-1251, 2007
44. Nicholls SJ, Dusting GJ, Cutri B, Bao S, Drummond GR, Rye KA, Barter PJ: Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111:1543-1550, 2005
45. Lip PL, Chatterjee S, Caine GJ, Hope-Ross M, Gibson J, Blann AD, Lip GY: Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photo-coagulation and angiotensin receptor blockade. Br J Ophthalmol 88:1543-1546, 2004